Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?

Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?

Bibliographic Details
Main Author:	Sang-Gon Park
Format:	Article
Language:	English
Published:	The Korean Association of Internal Medicine 2019-07-01
Series:	The Korean Journal of Internal Medicine
Online Access:	http://www.kjim.org/upload/pdf/kjim-2019-182.pdf

Similar Items

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
by: Kyoung Min Cho, et al.
Published: (2019-07-01)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
by: Zhang N, et al.
Published: (2016-10-01)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
by: Steven Habbous, et al.
Published: (2020-10-01)

Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
by: Johnson, Nathalie
Published: (2010)

Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
by: Johnson, Nathalie
Published: (2010)

Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
by: Johnson, Nathalie
Published: (2010)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
by: Carrasquillo J, et al.
Published: (2009-06-01)

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
by: Nway Le Ko Ko, et al.
Published: (2020-10-01)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.
by: Xuan Zhou, et al.
Published: (2017-01-01)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
by: R. Palmieri, et al.
Published: (2019-01-01)

Comparative Study on Rituximab Combined with Chemotherapy and Single Chemotherapy for Diffuse Large B Cell Lymphoma
by: Ji-feng FENG
Published: (2015-06-01)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
by: Sotirios G. Papageorgiou, et al.
Published: (2021-05-01)

Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma
by: Adriano M. Pellicelli, et al.
Published: (2015-09-01)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
by: Myrna Candelaria, et al.
Published: (2021-01-01)

Cryptococcemia in an Elderly Woman with Retroperitoneal Diffuse Large B-cell Lymphoma after Rituximab-containing Chemotherapy
by: Ming-Wei Cheng, et al.
Published: (2016-06-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
by: Koh Ki-Ryang, et al.
Published: (2009-08-01)

MicroRNAs are Related to Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Resistance in Patients with Diffuse Large B-cell Lymphoma
by: Haibo Huang, et al.
Published: (2015-01-01)

Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen
by: C H Chang, et al.
Published: (2020-01-01)

Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?
by: WM Tai MBBS(S'pore), MRCP(UK), et al.
Published: (2011-03-01)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
by: Yuankai Shi, et al.
Published: (2020-04-01)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
by: Feifei Sun, et al.
Published: (2018-01-01)

Intravitreal rituximab for the treatment of a secondary intraocular relapse of a large B-cell lymphoma
by: Jose J. Echegaray, et al.
Published: (2018-03-01)

Diffuse large B cell lymphoma: prognostic factors in the rituximab era = Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab
by: Natalia María Guevara Arismendy, et al.
Published: (2013-07-01)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
by: Lee YP, et al.
Published: (2021-05-01)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
by: Kim Yu, et al.
Published: (2012-08-01)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
by: Narendranath Epperla, et al.
Published: (2020-08-01)

Impact of rituximab on standard chemotherapy for diffuse large B-cell lymphoma subtyping using a new immunohistochemistry algorithm
by: Sissolak, Gerhard
Published: (2011)

Excellent response of rituximab and bendamustine in elderly patient with relapsed diffuse large B-cell lymphoma: a case report
by: Wiwiek Probowati, et al.
Published: (2021-01-01)

Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
by: Yuan-Rong Ren, et al.
Published: (2015-01-01)

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
by: Roland Christian Schelker, et al.
Published: (2018-10-01)

Rituximab for primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp
by: Čolović Nataša, et al.
Published: (2008-01-01)

Endogenous neurotrophins and Trk signaling in diffuse large B cell lymphoma cell lines are involved in sensitivity to rituximab-induced apoptosis.
by: Cynthia Bellanger, et al.
Published: (2011-01-01)

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study
by: David Belada, et al.
Published: (2007-01-01)

Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
by: Armansyah, A., et al.
Published: (2022)

Transient Wheal Attack Corresponding to the Tumor Lesions of Primary Cutaneous Diffuse Large B Cell Lymphoma, Leg Type after Successive Rituximab Treatment
by: Saori Itoi, et al.
Published: (2014-09-01)

Large-Cell Neuroendocrine Cancer of the Colon following Rituximab-Based Lymphoma Treatment
by: Hugh J Freeman, et al.
Published: (2012-01-01)

A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib
by: Geoffrey Shouse, et al.
Published: (2018-01-01)

Diffuse Large B-Cell Lymphoma Transformed from Mucosa-Associated Lymphoid Tissue Lymphoma Arising in a Female Urethra Treated with Rituximab for the First Time
by: A. Al Zahrani, et al.
Published: (2012-05-01)